Getty Images Pharmaceutical company Eli Lilly is expected to report fourth-quarter earnings before the bell Thursday. Analysts tracking the company see increased sales and profit for Eli Lilly in ...

Eli Lilly's stock price finished Jan. 16 down 21% from a peak it set last September. The sales trajectory of Mounjaro and Zepbound tapered off in the second half of 2024. An oral weight-loss ...

Boris Becker's ex-wife Lilly has won the German version of I'm A Celebrity... Get Me Out Of Here! after stealing the hearts of the nation. The former Wimbledon tennis star, 57, has endured a ...

Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes ...

The actress and her husband are now mom and dad to Tove Jane McDowell Gettty;Lily Collins/Instagram Lily Collins and Charlie McDowell are parents! The Emily in Paris actress, 35, and the film ...

In this article, we are going to take a look at where Eli Lilly And Co. (NYSE:LLY) stands against other stocks that could split in the near future. Stock splits don’t change how much a company ...

Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels.

OnlyFans sensation Lily Phillips has sparked outrage again with yet another shocking sex stunt. After going viral late last year for bedding 100 men in a single night, the English performer ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

It is the largest study ever of the drug category—which includes Novo Nordisk’s GLP-1 treatments Ozempic and Wegovy and Eli Lilly’s dual-action GLP-1/GIP agonists Mounjaro and Zepbound.

Trump's tariffs may or may not make Lilly a no-brainer stock in 2025. Still, I think it's a great stock to buy no matter what happens politically. Don’t miss this second chance at a potentially ...